The overall production for the entire process is 22 million doses per year. This production
capacity is approximately the same as a medium sized facility. Using a baculovirus insect cell
expression system can reduce the production time of influenza vaccines from 6 months to 4
months. The other cell line considered, Chinese Hamster Ovaries, was determined to be
unfavorable due to safety concerns. It was determined that disposable technology would be ideal
for the process, as it allows production scale up with minimal capital investment. The disposable
technology employed in the facility was found to be more economically viable than conventional
multi-use technology. The facility still requires the use of some multi-use components, such as
chromatography and diafiltration, but single use technology is employed where possible.
Examining the project, a lifespan of 23 years was determined to be appropriate for demonstrating
the economic feasibility of the project. It was found that the minimum IRR at current prices was
33.36%. With a 12% discrete interest rate, the net present value of the facility is $278 million,
for a total capital investment of $149 million. At this rate, it was also determined that the
payback period was 2.83 years with a return on investment of 34.42%. From this data, it was
concluded that the project should proceed as planned.
Except where otherwise noted, the use of this item is bound by the following: This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).